Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard Auclin

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
Nature Communications|September 2, 2021
Integrin-α<sub>V</sub>-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeInes Malenica, Julien Adam, Stéphanie Corgnac, et al.
European Urology Oncology|April 22, 2026
Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 TrialsCharles Vauchier, Constance Thibault, Maud Velev, et al.
Annals of Intensive Care|March 8, 2017
Outcomes in elderly patients admitted to the intensive care unit with solid tumorsEdouard Auclin, Anaïs Charles-Nelson, Baptiste Abbar, et al.
British Journal of Cancer|January 30, 2022
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO studySonia Zaibet, Vincent Hautefeuille, Edouard Auclin, et al.
Clinical Colorectal Cancer|October 26, 2019
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter StudyMarie Auvray, David Tougeron, Edouard Auclin, et al.
The Oncologist|February 8, 2021
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell CarcinomaElie Rassy, Luigi Cerbone, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancerAdrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.
Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.
Frontiers in Oncology|June 7, 2021
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective StudyNicolas Epaillard, Pauline Parent, Yohann Loriot, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Nature Communications|September 2, 2021
Integrin-α<sub>V</sub>-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeInes Malenica, Julien Adam, Stéphanie Corgnac, et al.
European Urology Oncology|April 22, 2026
Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 TrialsCharles Vauchier, Constance Thibault, Maud Velev, et al.
Annals of Intensive Care|March 8, 2017
Outcomes in elderly patients admitted to the intensive care unit with solid tumorsEdouard Auclin, Anaïs Charles-Nelson, Baptiste Abbar, et al.
British Journal of Cancer|January 30, 2022
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO studySonia Zaibet, Vincent Hautefeuille, Edouard Auclin, et al.
Clinical Colorectal Cancer|October 26, 2019
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter StudyMarie Auvray, David Tougeron, Edouard Auclin, et al.
The Oncologist|February 8, 2021
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell CarcinomaElie Rassy, Luigi Cerbone, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancerAdrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.
Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.
Frontiers in Oncology|June 7, 2021
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective StudyNicolas Epaillard, Pauline Parent, Yohann Loriot, et al.
Pageof 9